Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. - Wikidata - awgldk - TriplyDB

Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.

Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.

http://www.wikidata.org/entity/Q34726541

about

Recognition of lipopolysaccharide pattern by TLR4 complexes Computational Approaches to Toll-Like Receptor 4 Modulation Balancing Innate Immunity and Inflammatory State via Modulation of Neutrophil Function: A Novel Strategy to Fight Sepsis Targeting Toll-like receptors with small molecule agents Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases Sepsis pathophysiology and anesthetic consideration Discovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors A key role for the endothelium in NOD1 mediated vascular inflammation: comparison to TLR4 responses Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update.Toll-like receptor 4 mediates endothelial cell activation through NF-κB but is not associated with endothelial dysfunction in patients with rheumatoid arthritis Toll-like receptor 4 plays a central role in cardiac dysfunction during trauma hemorrhage shock Novel synthetic toll-like receptor 4/MD2 ligands attenuate sterile inflammation The gut microbiome, kidney disease, and targeted interventions.Alternatively spliced myeloid differentiation protein-2 inhibits TLR4-mediated lung inflammation.Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling.Morphine activates neuroinflammation in a manner parallel to endotoxin Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death Biology and Metabolism of Sepsis: Innate Immunity, Bioenergetics, and Autophagy Identification of sepsis subtypes in critically ill adults using gene expression profiling Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and attenuates neuropathic pain.Conformationally constrained lipid A mimetics for exploration of structural basis of TLR4/MD-2 activation by lipopolysaccharide.sTLR4/MD-2 complex inhibits colorectal cancer in vitro and in vivo by targeting LPS.Zhankuic acid A isolated from Taiwanofungus camphoratus is a novel selective TLR4/MD-2 antagonist with anti-inflammatory properties.A novel small molecule, HK-156, inhibits lipopolysaccharide-induced activation of NF-κB signaling and improves survival in mouse models of sepsis.Acute kidney injury: a conspiracy of Toll-like receptor 4 on endothelia, leukocytes, and tubules.Anti-inflammatory mechanisms and therapeutic opportunities in myocardial infarct healing.Modulating immunity as a therapy for bacterial infections.Diagnosis and management for urosepsis.Drugs to cure avian influenza infection--multiple ways to prevent cell death Toll-like receptor regulation of intestinal development and inflammation in the pathogenesis of necrotizing enterocolitis.TLR4 signalling in osteoarthritis--finding targets for candidate DMOADs.Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics.Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling.Glycolipid-based TLR4 Modulators and Fluorescent Probes: Rational Design, Synthesis, and Biological Properties.MD-2 as the target of a novel small molecule, L6H21, in the attenuation of LPS-induced inflammatory response and sepsis Prebiotics: A Novel Approach to Treat Hepatocellular Carcinoma.Progress in the synthesis and biological evaluation of lipid A and its derivatives.The gut microbiome and liver cancer: mechanisms and clinical translation.Bolstering Immunity through Pattern Recognition Receptors: A Unique Approach to Control Tuberculosis.

P2860

Q24622138-A83F4350-CF54-4782-AC9F-CA4DA1B4BF85 Q26740008-47143B84-C6A3-49FE-954C-F32A508A806B Q26769674-DE925A4F-16A8-4ED0-AF9F-E691B8B85A67 Q26992220-12188ABE-BC4F-4943-AF34-643B8DCB0369 Q27010345-32A61397-0BF4-4199-BE7A-64AF7447C5EF Q28084129-418790AB-3568-4863-996A-D3123E3B1223 Q28533856-B105AB2A-FD30-4AAB-A579-1442B28B6288 Q28580003-AE04FBB1-AEB0-476F-89DB-56B122BD0477 Q33693637-2187A70F-77DA-4D8D-B3C2-47EFF80057D6 Q33740199-B4A0F744-E254-4275-838F-9569AC277E06 Q33756786-4AE4D5D4-715C-496A-A25E-CE47676A75EC Q33944008-7BD2E1EB-86D7-437C-96AB-02E34ABF2B0C Q35042986-7FB4A163-A695-4DDA-9927-BAD5E860C46D Q35071375-49D52F16-5ABC-4229-BB94-511B02EC0FAF Q35192812-5FD25D2A-BC11-491F-8230-F46C41A88494 Q35924760-8DC672E4-3D9F-4F3A-AF35-6F6BCD471747 Q35977675-D5E71C11-5547-4CD2-9EA1-2D303C999096 Q36469613-691E8D05-D7F8-413F-BEFF-780FC2A4D140 Q36925803-7801C3A7-074F-4E27-9B77-E6A4DA41A80A Q36928191-F4A0A624-99FB-4808-B563-80996EE642CC Q36945155-8342DF35-A6D1-4B77-A67C-A5EB8ED78800 Q37323250-0787E3DE-7E1A-41E0-8379-D5EBFCBEC62A Q37588407-AA282CD7-4AA2-4943-ABEC-EF04402C752F Q37627728-EBAF08C4-8E17-40F1-866C-0D11D3A9EBF8 Q37729477-6A3C7280-A682-4915-A89A-90215E1A2935 Q37950251-3CF5D747-A550-4C6F-B34B-CEE68F8383F8 Q37974118-1E9F0A3E-8C96-45EC-8597-BDBDC12E564C Q37994068-F3E0447C-CA3E-4136-B291-C9D87536CC4D Q38109961-1A6927A6-095F-4A5D-91A3-083F35794B8E Q38148960-6A2C35D4-3CCE-401C-AA5A-A85861DB79E6 Q38173600-2ED63620-CF9E-40C4-8A22-CC5E079DE263 Q38289811-1A1B4026-0ED4-4194-906C-9F257CCFAB72 Q38557048-A36AC0A3-32A4-47CB-9514-8018B4517D92 Q38695565-184EF46A-5471-46E2-9709-BCD1F88191F1 Q38792526-01888B18-4191-46E0-9715-96C06F3A61B7 Q38863938-30FA1D39-7BBF-4DE3-91BA-7CB8784D9E90 Q39345313-AA24B4B2-7791-40F4-BB3F-2494B9F6FDE4 Q39378325-ECF2132C-2B67-49B1-AFD3-69C74A95322B Q39414187-213AC5B9-A6EA-4B9A-A106-A4875CBB2C08 Q40086314-6C4E2EA0-2D66-4F04-98AF-4AAE5CDFBBE5

P2860

Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.

http://www.wikidata.org/entity/Q34726541

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Eritoran tetrasodium (E5564) t ...... clinical and clinical studies.

@ast

Eritoran tetrasodium (E5564) t ...... clinical and clinical studies.

@en

Eritoran tetrasodium

@nl

type

label

Eritoran tetrasodium (E5564) t ...... clinical and clinical studies.

@ast

Eritoran tetrasodium (E5564) t ...... clinical and clinical studies.

@en

Eritoran tetrasodium

@nl

prefLabel

Eritoran tetrasodium (E5564) t ...... clinical and clinical studies.

@ast

Eritoran tetrasodium (E5564) t ...... clinical and clinical studies.

@en

Eritoran tetrasodium

@nl

P1433

Q34726541-2A547044-551C-4B12-9969-D63E2FA82EA6

P1476

Q34726541-4DA0A923-A45A-4987-86C0-DDD63D3107CA

P2093

Q34726541-33E005A9-BEE9-48DA-B0ED-0F9586E05684

Q34726541-B106432C-CFE7-4CCA-B020-1D5C9E0C6BB1

Q34726541-D5BC5D9D-0131-49E8-922D-B1249CF75D10

Q34726541-DBBA3181-4E1F-4635-8D76-2A0A00E9C45A

Q34726541-E9C4D683-8F55-46A0-B7D4-57753514BD3B

P2860

Q34726541-0052AE60-1BC7-4DBF-A9E7-EBF487A730DA

Q34726541-03533A15-3349-4D67-876E-0589ECA1952A

Q34726541-0DB45AE3-B836-4B61-AA73-8F57812EDA75

Q34726541-0F6B52C0-0C4A-403C-8886-A7027BC86015

Q34726541-1367E09E-F301-4926-84A8-42C9287A74FC

Q34726541-1BE3C861-28C2-4600-8072-8DBBCB319ED2

Q34726541-1D276630-AD6D-446B-8CD9-C8B8AC180402

Q34726541-23A0E7A8-F938-4B38-BC49-0ED670AE21B9

Q34726541-28BEF692-2709-4CBB-BB9E-CE0C3E69A4D9

Q34726541-3968BED4-ACEF-4832-878B-156975BF9185

P304

Q34726541-2E5247F5-153D-4604-BAEB-29C7333E9DE6

P31

Q34726541-917EA0A1-0669-499E-8357-461E281E6421

P356

Q34726541-DD8EDAB0-9A37-47D1-BB56-C7806A248F6C

P407

Q34726541-3D91EF08-C2B9-4B96-8D2E-801AF8E7A3C9

P433

Q34726541-9797CEC5-53E3-4441-8E73-A299AE856730

P478

Q34726541-CC508C2B-A814-4EE4-8D31-8AC46E90EF63

P577

Q34726541-67C71038-E9C0-4828-960D-C94A5B6840C7

P5875

Q34726541-DBF62FBD-472D-4448-B221-7C94E3529A3B

P698

Q34726541-4428717D-2F1D-43C0-A1F6-7DB6943FD420

P921

Q34726541-F624D8C5-AE46-4C33-B649-3B2F9E15832F

P932

Q34726541-71137688-E8FE-4784-A4F2-EC8AB0AF9F15

P356

17425255.2011.558190

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

Eritoran tetrasodium (E5564) t ...... clinical and clinical studies.

@en

P2093

Amisha Barochia

http://www.w3.org/2001/XMLSchema#string

Charles Natanson

http://www.w3.org/2001/XMLSchema#string

Peter Q Eichacker

http://www.w3.org/2001/XMLSchema#string

Steven Solomon

http://www.w3.org/2001/XMLSchema#string

Xizhong Cui

http://www.w3.org/2001/XMLSchema#string

P2860

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran

The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex

Innate immune recognition

E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators

Toll-like receptors in the induction of the innate immune response

Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group

High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes

P304

479-494

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2011.558190

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49838368

http://www.w3.org/2001/XMLSchema#string

P698

21323610

http://www.w3.org/2001/XMLSchema#string

P921

P932

3065179

http://www.w3.org/2001/XMLSchema#string